Upregulation of the EP1 receptor for prostaglandin E2 promotes skin tumor progression

Molecular Carcinogenesis

Volumn 50, Issue 6, 2011, Pages 458-468

  Surh, Inok ^a   Rundhaug, Joyce ^a   Pavone, Amy ^a   Mikulec, Carol ^a   Abel, Erika ^a   Fischer, Susan M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

COX 2; Eicosanoids; Skin carcinogenesis

Indexed keywords

CYCLOOXYGENASE 2; DIMETHYLBENZ[A]ANTHRACENE; DITHRANOL; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROTEIN KINASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; TRANSGENIC MOUSE; TUMOR GROWTH;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENS; CELL PROLIFERATION; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE PROGRESSION; EPIDERMIS; FEMALE; HUMANS; MICE; MICE, HAIRLESS; MICE, TRANSGENIC; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; ULTRAVIOLET RAYS; UP-REGULATION;

MURINAE; MUS; MUS MUSCULUS;

EID: 79955722976     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20730     Document Type: Article

References (49)

1. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437.
2. Wang Z. The role of COX-2 in oral cancer development, and chemoprevention/treatment of oral cancer by selective COX-2 inhibitors. Curr Pharm Des 2005;11:1771-1777.
3. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003;24:96-102.
4. Kagoura M, Toyoda M, Matsui C, Morohashi M. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J Cutan Pathol 2001;28:298-302.
5. Muller-Decker K, Kopp-Schneider A, Marks F, Seibert K, Furstenberger G. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog 1998;23:36-44.
6. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-240.
7. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939-1944.
8. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-408.
9. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003;24:985-990.
10. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors. Cancer Res 2002;62:6706-6711.
11. Tiano HF, Loftin CD, Akunda J, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002;62:3395-3401.
12. Fischer SM, Pavone A, Mikulec C, Langenbach R, Rundhaug JE. Cyclooxygenase-2 expression is critical for chronic UV-induced murine skin carcinogenesis. Mol Carcinog 2007;46:363-371.
13. Rundhaug JE, Pavone A, Kim E, Fischer SM. The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent. Mol Carcinog 2007;46:981-992.
14. Fischer SM, Cameron GS, Baldwin JK, Jasheway DW, Patrick KE. Reactive oxygen in the tumor promotion stage of skin carcinogenesis. Lipids 1988;23:592-597.
15. Wendum D, Masliah J, Trugnan G, Flejou JF. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 2004;445:327-333.
16. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005;65:1822-1829.
17. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: Structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
18. Konger RL, Billings SD, Thompson AB, et al. Immunolocalization of low-affinity prostaglandin E receptors, EP and EP, in adult human epidermis. J Invest Dermatol 2005;124:965-970.
19. Lee JL, Kim A, Kopelovich L, Bickers DR, Athar M. Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 2005;125:818-825.
20. Neumann M, Dulsner E, Furstenberger G, Muller-Decker K. The expression pattern of prostaglandin E synthase and EP receptor isoforms in normal mouse skin and preinvasive skin neoplasms. Exp Dermatol 2007;16:445-453.
21. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001;7:1048-1051.
22. Sung YM, He G, Hwang DH, Fischer SM. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 2006;25:5507-5516.
23. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-9311.
24. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002;62:28-32.
25. Tober KL, Wilgus TA, Kusewitt DF, Thomas-Ahner JM, Maruyama T, Oberyszyn TM. Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006;126:205-211.
26. Niho N, Mutoh M, Kitamura T, et al. Suppression of azoxymethane-induced colon cancer development in rats by a prostaglandin E receptor EP1-selective antagonist. Cancer Sci 2005;96:260-264.
27. Makita H, Mutoh M, Maruyama T, et al. A prostaglandin E2 receptor subtype EP1-selective antagonist, ONO-8711, suppresses 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis. Carcinogenesis 2007;28:677-684.
28. Kawamori T, Uchiya N, Nakatsugi S, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 2001;22:2001-2004.
29. Kawamori T, Kitamura T, Watanabe K, et al. Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 2005;26:353-357.
30. Casatorres J, Navarro JM, Blessing M, Jorcano JL. Analysis of the control of expression and tissue specificity of the keratin 5 gene, characteristic of basal keratinocytes. Fundamental role of an AP-1 element. J Biol Chem 1994;269:20489-20496.
31. Thompson EJ, Gupta A, Vielhauer GA, Regan JW, Bowden GT. The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1. Neoplasia 2001;3:402-410.
32. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005;65:6275-6281.
33. Battalora MS, Johnston DA, DiGiovanni J. The effects of calcium antagonists on anthrone skin tumor promotion and promoter-related effects in SENCAR mice. Cancer Lett 1995;98:19-25.
34. Suda M, Tanaka K, Sakuma Y, et al. Prostaglandin E(2) (PGE(2)) induces the c-fos and c-jun expressions via the EP(1) subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells. Calcif Tissue Int 2000;66:217-223.
35. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem 2005;280:24053-24063.
36. Kimura M, Osumi S, Ogihara M. Prostaglandin E(2) (EP(1)) receptor agonist-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes: The involvement of TGF-alpha. Endocrinology 2001;142:4428-4440.
37. Muller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002;99:12483-12488.
38. Bol DK, Rowley RB, Ho CP, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002;62:2516-2521.
39. Reddig PJ, Dreckschmidt NE, Ahrens H, et al. Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1999;59:5710-5718.
40. Breitkreutz D, Braiman-Wiksman L, Daum N, Denning MF, Tennenbaum T. Protein kinase C family: On the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol 2007;133:793-808.
41. Verma AK, Wheeler DL, Aziz MH, Manoharan H. Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer. Mol Carcinog 2006;45:381-388.
42. Wang HQ, Smart RC. Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion. J Cell Sci 1999;112:3497-3506.
43. Suda M, Tanaka K, Yasoda A, et al. Prostaglandin E2 (PGE2) autoamplifies its production through EP1 subtype of PGE receptor in mouse osteoblastic MC3T3-E1 cells. Calcif Tissue Int 1998;62:327-331.
44. Imamoto A, Beltran LM, DiGiovanni J. Evidence for autocrine/paracrine growth stimulation by transforming growth factor-alpha during the process of skin tumor promotion. Mol Carcinog 1991;4:52-60.
45. Kiguchi K, Beltran L, Rupp T, DiGiovanni J. Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol. Mol Carcinog 1998;22:73-83.
46. Xian W, Kiguchi K, Imamoto A, Rupp T, Zilberstein A, DiGiovanni J. Activation of the epidermal growth factor receptor by skin tumor promoters and in skin tumors from SENCAR mice. Cell Growth Differ 1995;6:1447-1455.
47. DiGiovanni J, Rho O, Xian W, Beltran L. Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis. Prog Clin Biol Res 1994;387:113-138.
48. Su JL, Shih JY, Yen ML, et al. Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: A novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res 2004;64:554-564.
49. DiGiovanni J, Kruszewski FH, Coombs MM, Bhatt TS, Pezeshk A. Structure-activity relationships for epidermal ornithine decarboxylase induction and skin tumor promotion by anthrones. Carcinogenesis 1988;9:1437-1443.